Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 14:29:19·⟳ 抓取 14:29:51 +32s·⚡ 决策 10-19 20:01:34 +5h31m·8.1 天前
GSK公布B7-H3 ADC药物Ris-Rez小细胞肺癌全球首批1b期数据：8mg/kg剂量ORR 61%，推进全球III期
这是GSK一条早期（1b期、50人）剂量优化数据，全球III期此前已启动，授权方翰森在中国的III期已于2026年7月读出阳性，本次属于增量确认而非新的风险消除节点：对GSK超大市值无业绩增量，对翰森不带来可确认的新付款/收入，且港股今日交易时段已过、反应温和（+1.15%），伦敦GSK盘中微跌，均无正期望edge。
📄 原文Investing.com↗ 原文
GSK reports positive phase 1b data for lung cancer drug candidate
Buy these 2 stocks amid AI financing concerns: Analyst LONDON - GSK plc (LSE/NYSE:GSK) announced Sunday the first globa…
不做 GSK plc（GSK.GB）
超大市值药企的早期1b剂量优化数据、III期早已启动，无收入或指引增量，官方新闻稿后伦敦盘中微跌，属不具materiality的软催化；实时报价工具故障但不影响该结论
不做 翰森制药（03692.HK）
Ris-Rez大中华区权益的核心催化（中国III期阳性）已于7月兑现，本次为海外1b剂量确认、无可确认新增里程碑付款；港股周一已收盘、当日仅+1.15%，下一交易时段追入无edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Ris-Rez 1b期数据阳性并确认III期剂量，方向正面但属预期内的早期管线进展；对GSK市值不构成增量，对翰森只是海外管线的间接验证、无新里程碑确认，两地市场反应平淡，不做。
消息传播链
- GSK于10月16日预告ESMO 2026将公布首批全球Ris-Rez数据，读出时点市场提前可知
- ESMO正式公布1b数据：8mg/kg ORR 61%，选定该剂量推进已开展的全球III期
- 聚合媒体转述官方新闻稿，非首发；属二手扩散
- GSK伦敦盘中约-0.3%（TipRanks快照），翰森3692.HK当日收31.74港元、+1.15%，均无显著同向重定价，印证催化增量有限市场反应:GSK微跌；翰森+1.15%后港股已收盘
关键理由
- 数据本身积极（ORR 61%、剂量确定、III期推进），但相对事件前预期仅消除少量剂量选择风险，资产前景已被翰森中国III期阳性大幅定价
- 无任何主体在本次事件中产生近期收入、指引或可确认付款增量，不满足超大市值软催化的可交易升级条件
主要风险
- 8mg/kg组≥3级不良事件42%、血液学毒性突出，全球III期安全性与OS仍可能失败，早期ORR不可外推
- 若授权协议将剂量确认/III期推进列为里程碑，翰森可能存在未预期的小额付款利好；本轮未能核实合同条款明细
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 weakens
8mg/kg组≥3级TRAE达42%、以血液学毒性为主，安全性代价明显；且全球III期尚在进行，1b的18人可评估样本ORR不能转化为近期现金流
检索:Ris-Rez ESMO 2026 data criticism safety ILD phase III risk GSK Hansoh 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 invalidates
GSK伦交所盘中微跌约0.3%，翰森港股仅+1.15%后收盘，无跳空放量，价格本身否定存在未被定价的短期edge
检索:GSK.L 2026-10-19 股价 反应 ris-rez 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例与当日盘面共同支持AVOID：不设任何ENTER腿，不编造tp/sl
方向:未构建可对照先例面板：GSK伦交所/ADR实时报价工具本轮故障，且无法在本轮以一手首发源可靠锚定足够数量的'大药企授权引进ADC早期数据读出'同市场先例
涨幅量级:不足：无干净aligned样本校准幅度；但当日两个权益方的真实市场反应（GSK微跌、翰森+1.15%）本身已直接表明市场给该事件的定价极低
形态:未见可交易的跳空/放量同向重定价模式
工具执行结果 · 成功 4 · 降级 0 · 失败 2 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`gsk adc 61% orr relapsed extensive-stage sclc 8mg/kg | gsk risvutatug rezetecan esmo 2026 phase 1b small cell lung cancer | 翰森制药 risvutatug rezetecan gsk 授权 embold 数据`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 失败 stock_tools HTTP · 9 ms
行情服务暂不可用；本次无法核验该标的价格和可执行条件。请基于其余证据继续判断并明确标注行情降级；不得仅因工具故障自动给出 AVOID 或 ENTER，也不得编造价位。 - stock_quote 成功 stock_tools HTTP · 353 ms
{ - web_search 成功 doubao_search · 1,827 ms
豆包搜索结果（原始查询:GSK risvutatug rezetecan ESMO 2026 phase 1b small cell lung cancer ORR 61% press release；API SearchType:web） - kb_search 失败 stock_tools HTTP · 57 ms
kb_search 服务暂不可用；这不是一条知识库命中。
原文全文
展开原文 · 2,071 字
Buy these 2 stocks amid AI financing concerns: Analyst
LONDON - GSK plc (LSE/NYSE:GSK) announced Sunday the first global data for risvutatug rezetecan, an investigational antibody-drug conjugate, in patients with relapsed extensive-stage small cell lung cancer.
The phase Ib dose-optimization portion of the EMBOLD PanTumour-101 trial showed a confirmed objective response rate of 61% among evaluable patients at the 8 mg/kg dose, compared with 32% at the 6 mg/kg dose, according to a press release statement. The findings were presented at the European Society for Medical Oncology Congress 2026 in Madrid.
The trial enrolled 50 patients with relapsed extensive-stage small cell lung cancer who had received a median of two prior therapies. At the 8 mg/kg dose, 11 out of 18 evaluable patients responded, while 7 out of 22 patients responded at the 6 mg/kg dose.
Grade 3 or higher treatment-related adverse events occurred in 42% of patients receiving 8 mg/kg and 15% of those receiving 6 mg/kg at a median follow-up of 100.5 days. Haematological events were the most common. The overall rate of interstitial lung disease was 2%, with one moderate case among 50 patients.
The data supported selection of the 8 mg/kg dose for GSK’s global phase III EMBOLD SCLC-301 study, currently underway.
GSK acquired worldwide rights to risvutatug rezetecan from Hansoh Pharma, excluding mainland China, Hong Kong, Macau and Taiwan. More than 1,000 patients have received the drug as part of GSK’s EMBOLD clinical trial program, which includes phase III trials in extensive-stage small cell lung cancer and metastatic castration-resistant prostate cancer.
Small cell lung cancer accounts for approximately 10-15% of all lung cancer diagnoses worldwide. Approximately 70% of patients are diagnosed with extensive-stage disease. Median overall survival for patients with extensive-stage small cell lung cancer treated with current therapies is approximately 12 to 13 months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LONDON - GSK plc (LSE/NYSE:GSK) announced Sunday the first global data for risvutatug rezetecan, an investigational antibody-drug conjugate, in patients with relapsed extensive-stage small cell lung cancer.
The phase Ib dose-optimization portion of the EMBOLD PanTumour-101 trial showed a confirmed objective response rate of 61% among evaluable patients at the 8 mg/kg dose, compared with 32% at the 6 mg/kg dose, according to a press release statement. The findings were presented at the European Society for Medical Oncology Congress 2026 in Madrid.
The trial enrolled 50 patients with relapsed extensive-stage small cell lung cancer who had received a median of two prior therapies. At the 8 mg/kg dose, 11 out of 18 evaluable patients responded, while 7 out of 22 patients responded at the 6 mg/kg dose.
Grade 3 or higher treatment-related adverse events occurred in 42% of patients receiving 8 mg/kg and 15% of those receiving 6 mg/kg at a median follow-up of 100.5 days. Haematological events were the most common. The overall rate of interstitial lung disease was 2%, with one moderate case among 50 patients.
The data supported selection of the 8 mg/kg dose for GSK’s global phase III EMBOLD SCLC-301 study, currently underway.
GSK acquired worldwide rights to risvutatug rezetecan from Hansoh Pharma, excluding mainland China, Hong Kong, Macau and Taiwan. More than 1,000 patients have received the drug as part of GSK’s EMBOLD clinical trial program, which includes phase III trials in extensive-stage small cell lung cancer and metastatic castration-resistant prostate cancer.
Small cell lung cancer accounts for approximately 10-15% of all lung cancer diagnoses worldwide. Approximately 70% of patients are diagnosed with extensive-stage disease. Median overall survival for patients with extensive-stage small cell lung cancer treated with current therapies is approximately 12 to 13 months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
7bfeb4f7f5· 2026-10-19 20:01 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前